Definium Therapeutics, Inc. (DFTX)

SEC filing

Definium Therapeutics, Inc.

DFTX · CIK 1813814

4 · Sep 14, 2026 · Chief Commercial Officer Wiley Matthew T. was granted 125K Common Shares

Chief Commercial Officer Wiley Matthew T. was granted 125K Common Shares

Could not load the primary document from EDGAR (SEC rate limit, timeout, or temporary upstream error). Refresh in a minute, or use View on SEC.gov.